Antagonistic pleiotropy: the example of cardiac insulin-like growth factor signaling, which is essential in youth but detrimental in age

References

• López-Otín C, Kroemer G. Hallmarks of Health. Cell. 2021;184(1):33–63.
   PubMed Web of Science ®Google Scholar
• López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell. 2013;153(6):1194–1217.
   PubMed Web of Science ®Google Scholar
• Williams GC. Pleiotropy, natural selection, and the evolution of senescence. Evolution. 1957;11:398–411.
   Web of Science ®Google Scholar
• Kirkwood TB. Evolution of ageing. Nature. 1977;270:301–304.
   PubMed Web of Science ®Google Scholar
• Johnson AA, Shokhirev MN, Shoshitaishvili B. Revamping the evolutionary theories of aging. Ageing Res Rev. 2019;55(100947).
   PubMedGoogle Scholar
• Flatt T, Partridge L. Horizons in the evolution of aging. BMC Biol. 2018;16(93).
   PubMedGoogle Scholar
• Junnila RK, List EO, Berryman DE, et al. The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol. 2013;9:366–376.
   PubMed Web of Science ®Google Scholar
• Milman S, Huffman DM, Barzilai N. The somatotropic axis in human aging: framework for the current state of knowledge and future research. Cell Metab. 2016;23:980–989.
   PubMed Web of Science ®Google Scholar
• Rahmani J, Montesanto A, Giovannucci E, et al. Association between IGF-1 levels ranges and all-cause mortality: a meta-analysis. Aging Cell. 2022;21(e13540).
   PubMedGoogle Scholar
• Zhang WB, Ye K, Barzilai N, et al. The antagonistic pleiotropy of insulin-like growth factor 1. Aging Cell. 2021;20(e13443). DOI:10.1111/acel.13443.
   Google Scholar
• Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–152.
   PubMed Web of Science ®Google Scholar
• Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958–2003. J Clin Endocrinol Metab. 2004;89(3):1031–1044.
   PubMed Web of Science ®Google Scholar
• Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3(70):70ra13.
   PubMed Web of Science ®Google Scholar
• Moellendorf S, Kessels C, Peiseler L, et al. IGF-IR signaling attenuates the age-related decline of diastolic cardiac function. Am J Physiol Endocrinol Metab. 2012;303(E213–222):E213–E222.
   PubMedGoogle Scholar
• Ock S, Lee WS, Ahn J, et al. Deletion of IGF-1 receptors in cardiomyocytes attenuates cardiac aging in male mice. Endocrinology. 2016;157(1):336–345.
   PubMed Web of Science ®Google Scholar
• Abdellatif M, Trummer-Herbst V, Heberle AM, et al. Fine-tuning cardiac insulin-like growth factor 1 receptor signaling to promote health and longevity. Circulation. 2022;145(25):1853–1866.
   PubMed Web of Science ®Google Scholar
• Zimmermann A, Madreiter-Sokolowski C, Stryeck S, et al. Targeting the mitochondria-proteostasis axis to delay aging. Front Cell Dev Biol. 2021;9(656201). DOI:10.3389/fcell.2021.656201.
   Google Scholar
• Abdellatif M, Ljubojevic-Holzer S, Madeo F, et al. Autophagy in cardiovascular health and disease. Prog Mol Biol Transl Sci. 2020;172:87–106.
   PubMed Web of Science ®Google Scholar
• Abdellatif M, Sedej S, Carmona-Gutierrez D, et al. Autophagy in Cardiovascular Aging. Circ. Res. 2018;123(7):803–824.
   PubMed Web of Science ®Google Scholar
• Abdellatif M, Madeo F, Kroemer G, et al. Spermidine overrides INSR (insulin receptor)-IGF1R (insulin-like growth factor 1 receptor)-mediated inhibition of autophagy in the aging heart. Autophagy. 2022;1–3. DOI:10.1080/15548627.2022.2095835.
   PubMed Web of Science ®Google Scholar
• Beckwith H, Yee D. Minireview: were the IGF signaling inhibitors all bad? Mol Endocrinol. 2015;29(11):1549–1557.
   PubMedGoogle Scholar
• Nunnery SE, Mayer IA. Management of toxicity to isoform α-specific PI3K inhibitors. Ann Oncol. 2019;30:x21–x26.
   Web of Science ®Google Scholar
• Madeo F, Carmona-Gutierrez D, Hofer SJ, et al. Caloric restriction mimetics against age-associated disease: targets, mechanisms, and therapeutic potential. Cell Metab. 2019;29(3):592–610.
   PubMed Web of Science ®Google Scholar
• Eisenberg T, Abdellatif M, Schroeder S, et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat. Med. 2016;22(12):1428–1438.
   PubMed Web of Science ®Google Scholar
• Abdellatif M, Sedej S, Kroemer G. NAD + metabolism in cardiac health, aging, and disease. Circulation. 2021;144(22):1795–1817.
   PubMed Web of Science ®Google Scholar
• Abdellatif M, Trummer-Herbst V, Koser F, et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci Transl Med. 2021;13(eabd7064). DOI:10.1126/scitranslmed.abd7064.
   PubMedGoogle Scholar
• Gubbi S, Quipildor GF, Barzilai N, et al. 40 YEARS of IGF1: IGF1: the Jekyll and Hyde of the aging brain. J Mol Endocrinol. 2018;61:T171–T185.
   PubMed Web of Science ®Google Scholar
• Romanelli RJ, LeBeau AP, Fulmer CG, et al. Insulin-like growth factor type-I receptor internalization and recycling mediate the sustained phosphorylation of Akt. J Biol Chem. 2007;282:22513–22524.
   PubMed Web of Science ®Google Scholar
• Fang F, Goldstein JL, Shi X, et al. Unexpected role for IGF-1 in starvation: maintenance of blood glucose. Proc Natl Acad Sci U S A. 2022;119(e2208855119).
   Google Scholar
• Pascual M, Larralde J, Martínez JA. Insulin-like growth factor I (IGF-I) affects plasma lipid profile and inhibits the lipolytic action of growth hormone (GH) in isolated adipocytes. Life Sci. 1995;57:1213–1218.
   PubMed Web of Science ®Google Scholar
• Logan S, Pharaoh GA, Marlin MC, et al. Insulin-like growth factor receptor signaling regulates working memory, mitochondrial metabolism, and amyloid-β uptake in astrocytes. Mol Metab. 2018;9:141–155.
   PubMed Web of Science ®Google Scholar